Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Antibiotic drug that is usual topically used (Dermatology, ENT and Ophthalmology)
At latest update no published data on excretion into breast milk were found.
The small dose and low absorption to the plasma in a majority of preparations that are topically used on the eye, ear or skin make a significant excretion into the milk unlikely.
Its high molecular weight makes less probable an excretion into breast milk in significant amount.
Due to a poor oral bioavailability, appearance in the infant's plasma from ingested milk is regarded as nil or scanty, except in premature infants or during the immediate neonatal period who may show an increased intestinal absorption.
Polymyxin E or Colistin with a very similar molecular structure is excreted into breast milk in non-significant amount.
It is advisable to avoid the application of creams, gels and other products for local use that would contain paraffin (mineral oil) to prevent absorption by the infant.